Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

Official Title

An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Adults With Hypertrophic Cardiomyopathy

Keywords

Hypertrophic Cardiomyopathy, Cardiomyopathies, Hypertrophy, EDG-7500

Eligibility

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States
  • Stanford University Hospital / Stanford Health Care accepting new patients
    Stanford California 94305 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Edgewise Therapeutics, Inc.
ID
NCT06347159
Phase
Phase 2 Cardiomyopathy Research Study
Study Type
Interventional
Participants
Expecting 75 study participants
Last Updated